Small Molecule-Drug Conjugates: Opportunities for the Development of Targeted Anticancer Drugs.

Autor: Zhang J; School of Public Health, Health Science Center, Xi'an Jiaotong University, No.76 Yanta West Road, Xi'an, Shaanxi, 710061, China., Hu F; School of Public Health, Health Science Center, Xi'an Jiaotong University, No.76 Yanta West Road, Xi'an, Shaanxi, 710061, China., Aras O; Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA., Chai Y; Department of Oncology, The Second Affiliated Hospital of Xi'an, Jiaotong University, No.157 Xiwu Road, Xincheng District, Xi'an, Shaanxi, 710004, China., An F; School of Public Health, Health Science Center, Xi'an Jiaotong University, No.76 Yanta West Road, Xi'an, Shaanxi, 710061, China.
Jazyk: angličtina
Zdroj: ChemMedChem [ChemMedChem] 2024 Jun 03; Vol. 19 (11), pp. e202300720. Date of Electronic Publication: 2024 Mar 11.
DOI: 10.1002/cmdc.202300720
Abstrakt: Conventional chemotherapy is insufficient for precise cancer treatment due to its lack of selectivity and inevitable side effects. Targeted drugs have emerged as a promising solution for precise cancer treatment. A common strategy is to conjugate therapeutic agents with ligands that can specifically bind to tumor cells, providing targeted therapy. Similar to the more successful antibody drug conjugates (ADCs), small molecule drug conjugates (SMDCs) are another promising class of targeted drugs, consisting of three parts: targeting ligand, cleavable linker and payload. Compared to ADCs, SMDCs have the advantages of smaller size, better permeability, simpler preparation process and non-immunogenicity, making them a promising alternative to ADCs. This review describes the characteristics of the targeting ligand, linker and payload of SMDCs and the criteria for selecting a suitable one. We also discuss recently reported SMDCs and list some successful SMDCs that have entered clinical trials.
(© 2024 Wiley-VCH GmbH.)
Databáze: MEDLINE
Externí odkaz: